Application of traditional Chinese medicine composition in preparation of medicine for treating or preventing asthma

Abstract

The invention relates to application of a traditional Chinese medicine composition in a medicine for treating or preventing asthma. The traditional Chinese medicine composition is prepared from 100 to 400 parts of honeysuckle flower, 75 to 300 parts of radix puerariae, 100 to 400 parts of fructus forsythiae, 60 to 240 parts of fructus arctii, 60 to 240 parts of herba menthae, 60 to 240 parts of radix isatidis, 75 to 300 parts of rhizoma anemarrhenae, 50 to 200 parts of rhizoma cimicifugae and 30 to 120 parts of cicada slough. The traditional Chinese medicine composition can significantly inhibit airway inflammatory response, improve oxidative stress injury and relieve bronchial constriction, and has a good treatment effect on asthma.

Description

Technical Field

[0001] The invention belongs to the technical field of traditional Chinese medicines, relates to a new use of a traditional Chinese medicine composition, and specifically relates to the use of a traditional Chinese medicine composition in preparing a medicine for treating or preventing asthma. Background Art

[0002] Bronchial asthma (abbreviated as asthma), also known as asthma in domestic literature, is a chronic inflammatory disease of the airways involving multiple cells (such as mast cells, eosinophils, T lymphocytes, neutrophils, airway epithelial cells, etc.) and cell components. This chronic inflammation is associated with airway hyperresponsiveness, usually with widespread and variable reversible airflow limitation, and causes recurrent symptoms such as wheezing, shortness of breath, chest tightness, and cough, which often occur and worsen at night and (or) early morning. Most patients can relieve themselves or after treatment. If bronchial asthma is not diagnosed and treated in time, irreversible airway narrowing and airway remodeling may occur as the course of the disease prolongs. When asthma is controlled, most patients rarely have asthma attacks, and severe asthma attacks are even rarer. Data from the global burden of asthma show that although the cost of controlling asthma seems high from the perspective of patients and society, incorrect treatment can lead to repeated asthma attacks, and the cost of treatment will be higher.

[0003] Asthma belongs to the category of "asthma" in traditional Chinese medicine, and is mostly triggered by invasion of exogenous pathogens, improper diet, emotional disorders, physical weakness and fatigue. At present, the asthma medications recommended by domestic and foreign guidelines are mostly bronchodilators, theophylline, cholinergic receptor antagonists, hormones, etc. Although they can improve symptoms and relieve the condition to a certain extent, they still cannot cure asthma. Moreover, asthma is a heterogeneous disease with multiple clinical phenotypes. Traditional Chinese medicine treatment is relatively safe and will not cause many adverse reactions, but it also has defects such as long treatment time and slow initial effect. Therefore, more and more people are calling for the combination of Chinese and Western medicine to learn from each other's strengths and weaknesses, and research in this area has also made certain progress. Summary of the invention

[0004] In order to solve the above technical problems, the present invention provides a use of a Chinese medicine composition in the preparation of a drug for treating or preventing asthma, the Chinese medicine composition comprising: 100-400 parts of honeysuckle, 75-300 parts of kudzu root, 100-400 parts of forsythia, 60-240 parts of burdock, 60-240 parts of mint, 60-240 parts of isatis root, 75-300 parts of rhizoma anemarrhenae, 50-200 parts of cicada shells, and 30-120 parts of cicada shells. Further, the Chinese medicine composition comprises: 200-240 parts of honeysuckle, 150-180 parts of kudzu root, 200-240 parts of forsythia, 120-150 parts of burdock, 120-150 parts of mint, 120-150 parts of isatis root, 150-180 parts of rhizoma anemarrhenae, 100-120 parts of cicada shells, and 60-80 parts of cicada shells.

[0005] Preferably, the Chinese medicine composition comprises: 200 parts of honeysuckle, 150 parts of kudzu root, 200 parts of forsythia, 120 parts of burdock fruit, 120 parts of mint, 120 parts of isatis root, 150 parts of anemarrhena, 100 parts of cicada shell, and 60 parts of cicada shell.

[0006] The present invention also provides a use of any of the above-mentioned traditional Chinese medicine compositions in preparing drugs for treating or preventing inflammation.

[0007] The above composition, if in grams, can be made into a preparation with a dosage of 50-1000 times. For example, as tablets, 1000 tablets can be made, and each dosage can be 1-20 tablets, which can be taken 50-1000 times in total. If as granules, 125 bags can be made, and 1-2 bags can be taken each time, which can be taken 62.5-125 times in total.

[0008] The above composition is based on weight proportions, and can be increased or decreased in corresponding proportions during production. For example, large-scale production can be measured in kilograms or tons, and small-scale production can also be measured in milligrams. The weight can be increased or decreased, but the weight ratio of the raw medicinal materials between the components remains unchanged.

[0009] The above weight ratios are obtained through scientific screening. For special patients, such as those with severe or mild illnesses, obese or thin patients, the ratio of the components can be adjusted accordingly, with an increase or decrease of no more than 100%, and the efficacy remains unchanged.

[0010] Specifically, the drug for treating or preventing asthma includes pharmaceutically acceptable excipients or additives.

[0011] Specifically, the pharmaceutically acceptable excipients or additives include fillers, disintegrants, lubricants, suspending agents, binders, sweeteners, flavoring agents, preservatives, and bases.

[0012] Specifically, the dosage form of the drug includes an oral dosage form, an injection dosage form or an external dosage form.

[0013] The Chinese medicine preparation of the present invention can be any pharmaceutically acceptable dosage form, and these dosage forms include: tablets, sugar-coated tablets, film-coated tablets, enteric-coated tablets, capsules, hard capsules, soft capsules, oral liquids, lozenges, granules, electuary, pills, powders, pastes, pills, suspensions, powders, solutions, injections, suppositories, ointments, plasters, creams, sprays, drops, and patches. The preparation of the present invention is preferably an oral dosage form, such as: capsules, tablets, oral liquids, granules, pills, powders, pills, pastes, etc. Most preferably, tablets.

[0014] The preparation of the present invention is used in a dosage determined according to the patient's condition, and can be taken three times a day, 1-20 doses each time, such as 1-20 bags, granules or tablets.

[0015] The optional preparation method of the Chinese medicine preparation of the present invention is as follows:

[0016] Volatile oils of forsythia and mint are extracted by steam distillation, the obtained volatile oils are included in beta-cyclodextrin to obtain inclusion compounds, and the extract is filtered and set aside; after the oil is extracted, the residues are extracted with water, filtered, and the filtrate is combined with the steam distillation extract and set aside; the remaining seven ingredients are decocted with water, the extract is concentrated, cooled, ethanol is added, allowed to stand, filtered, the ethanol is recovered, dried, and dry powder is obtained, the volatile oil inclusion compound is added to obtain active pharmaceutical ingredients; the ingredients are prepared alone or mixed with pharmaceutically acceptable carriers to prepare the Chinese medicine preparation of the present invention according to conventional pharmaceutical preparation techniques.

[0017] For the preparation of tablets, the above active ingredients can be added with starch, sucrose, magnesium stearate and microcrystalline cellulose, mixed evenly, dry granulated, dried, granulated, tableted, film-coated and packaged.

[0018] Preferably, the preparation method of the traditional Chinese medicine composition comprises the following steps: adding 10 times the amount of water to two ingredients, Forsythia suspensa and mint, extracting volatile oil by steam distillation, the extraction time is 3.0 hours, filtering the extract and setting aside; the obtained volatile oil is included in 8 times the amount of β-cyclodextrin at 60°C for 3.0 hours to obtain an inclusion compound, which is set aside; adding 8 times the amount of water to the residue after oil extraction, extracting for 2.0 hours, filtering, combining the filtrate with the steam distillation liquid, and setting aside; adding water to seven ingredients including Pueraria lobata and boiling twice, each time for 2.0 hours, with 11 times the amount of water for the first time and 10 times the amount of water for the second time, boiling for 2.0 hours; The liquid is filtered, and the filtrates are combined for standby use; the above two filtrates are combined, concentrated under reduced pressure to a relative density of 1.07-1.09, cooled to room temperature, ethanol is slowly added to make the alcohol content reach 70%, fully stirred, left to stand for 18 hours, filtered, the filtrate is decompressed to recover ethanol until there is no alcohol taste, the liquid is diluted with water to a relative density of 1.03-1.05, spray dried, dry powder is obtained, the above volatile oil inclusion compound, starch, sucrose, appropriate amount of magnesium stearate and microcrystalline cellulose are added, mixed, dry granulated, dried, granulated, tableted, film coated, packaged, and obtained. The composition of the present invention can significantly reduce the degree of asthma inflammation in mice and improve the level of oxidative stress; it can significantly reduce the content of TGF-β1, MMP-9 and TIMP-1 in alveolar lavage fluid, and increase the content of T-AOC, SOD, GSH-Px and CAT in lung tissue, indicating that the Chinese medicine composition can significantly inhibit inflammation-induced bronchial mouse airway remodeling, reduce oxidative stress damage, and has a good therapeutic effect on mouse asthma. The composition of the present invention can significantly reduce the contents of TNFα, IL-4 and IL-1β in the serum and bronchoalveolar lavage fluid of asthmatic rats, and reduce the content of histamine in lung tissue, indicating that the Chinese medicine composition can significantly reduce the airway inflammation reaction of asthma, reduce bronchial contraction, and has a good therapeutic effect on rat asthma. DETAILED DESCRIPTION

[0019] As mentioned above, the present invention aims to provide a use of a Chinese medicine composition in the preparation of a drug for treating or preventing asthma. The following will be described in detail in conjunction with the contents of a specific experiment.

[0020] The following experiments, if no specific conditions are specified, were conducted under conventional conditions or conditions recommended by the manufacturer. The APIs or excipients, reagents or instruments used, if the manufacturer is not specified, are all conventional products that can be purchased commercially. Unless otherwise specified, all percentages, ratios, proportions or parts are by weight.

[0021] Unless otherwise defined, all professional and scientific terms used herein have the same meanings as those familiar to those skilled in the art. In addition, any methods and materials similar or equivalent to those described herein can be applied to the present invention.

[0022] Example 1 Preparation of the Composition Tablets of the Present Invention

[0023] The Chinese medicine composition of this embodiment is prepared from the following raw materials: 200g of honeysuckle, 150g of kudzu root, 200g of forsythia, 120g of burdock fruit, 120g of mint, 120g of isatis root, 150g of anemarrhena, 100g of cicada shell, and 60g of cicada shell.

[0024] The Chinese medicine composition is prepared according to the following method:

[0025] The above nine herbs, forsythia and mint, are added with 10 times the amount of water, and the volatile oil is extracted by steam distillation for 3.0 hours. The extract is filtered and set aside; the obtained volatile oil is included with 8 times the amount of β-cyclodextrin at 60°C for 3.0 hours to obtain an inclusion compound, which is set aside; after oil extraction, the residue is added with 8 times the amount of water, extracted for 2.0 hours, filtered, and the filtrate is combined with the steam distillation liquid for use; the seven herbs including Pueraria root are decocted with water twice, each time for 2.0 hours, 11 times the amount of water for the first time and 10 times the amount of water for the second time, the decoction is filtered, the filtrates are combined and set aside; the above two filtrates are combined and concentrated under reduced pressure to a relative The density is 1.07-1.09 (60°C), cooled to room temperature, ethanol is slowly added to make the alcohol content reach 70%, fully stirred, allowed to stand for 18 hours, filtered, the filtrate is decompressed (-0.085Mpa, 70-80°C) to recover ethanol until there is no alcohol taste, the drug solution is diluted with water to a relative density of 1.03-1.05 (20°C), spray dried to obtain dry powder, the above-mentioned volatile oil inclusion compound is added to obtain a composite intermediate, starch, sucrose, an appropriate amount of magnesium stearate and microcrystalline cellulose are added, mixed, dry granulated, dried, granulated, tableted, film coated, packaged, and the product is obtained.

[0026] Pharmacological tests

[0027] Experimental Example 2 Therapeutic Effect of Traditional Chinese Medicine Composition on OVA-Induced Mouse Asthma Model 1. Experimental Materials

[0028] 1.1 Animals

[0029] BALB / c mice, female, SPF grade, 60 mice, weighing 18-20 g, were purchased from the Comparative Medicine Center of Yangzhou University.

[0030] Breeding environment: room temperature 20-26°C, relative humidity controlled at 40-70%, animal breeding density 5 per cage.

[0031] 1.2 Drugs

[0032] Chinese medicine composition: the intermediate prepared according to Example 1, Jiangsu Kangyuan Pharmaceutical Co., Ltd.; ovalbumin OVA (Sigma, USA, batch number SLCB8249); aluminum hydroxide (Al(OH)3) (Aladdin, batch number: H2106415); salbutamol sulfate (Jiangsu Yabang Epson Pharmaceutical Co., Ltd., batch number: 201108); sodium pentobarbital (Beijing Chemical Reagent Company, batch number: 211122); physiological saline (Chenxin Pharmaceutical Co., Ltd., batch number: 2101282721).

[0033] 1.3 Instruments

[0034] Refrigerator (Haier Company, model: BCD-216SZ); electronic balance (Sartorius Scientific Instrument Company, model: BSA224S-CW); purified water instrument (Millipore Company, Germany, model: Milli-Q Plus); animal weight scale (Shanghai Xiangchuan Electronic Scale Co., Ltd., model: CX-SC-DA); multifunctional enzyme label reader (MD Company, USA, model: Flexstation 3); multifunctional cough and wheeze inducing instrument (Shanghai Xinruan Information Technology Co., Ltd., model: XR-YLS-8A).

[0035] 2. Dosage design

[0036] The daily dosage of the Chinese medicine composition is 14.64 g of crude drug / day. According to the body surface area conversion method, the equivalent dose for mice is 14.64 g / 60 kg*12.3=3 g of crude drug / kg. According to the 1 / 4:1 / 2:1 dosing method, the low dose is 0.75 g of crude drug / kg and the medium dose is 1.5 g of crude drug. Oral administration, 0.2 mL / 10 g, once a day.

[0037] The daily dosage of salbutamol sulfate is 10 mg / day. According to the body surface area conversion method, the equivalent dose for mice is 10 mg / 60 kg*12.3=2 mg / kg.

[0038] 3. Experimental Methods

[0039] BALB / c mice were adaptively fed for 3 days, with free access to feed and water, and were randomly divided into normal control group, model control group, salbutamol sulfate control group, and high, medium and low dose groups of Chinese medicine composition according to body weight, with 10 mice in each group. Except for the normal control group, all animals were sensitized by intraperitoneal injection of antigen mixture (ovalbumin (OVA) 100μg / mouse, aluminum hydroxide 2.25mg / mouse) on the 1st and 14th days, and the blank control group mice were intraperitoneally injected with an equal volume of normal saline. From the 21st day, the model group animals were given 40mL of 1% OVA aerosol solution for sensitization and stimulation every day, and the aerosol inhalation time was 30min / d for 7 consecutive days. The control group mice were given an equal volume of normal saline at the same time. At the same time, drug administration began from the 21st day, and the mice in the drug administration group were gavaged with positive drugs and corresponding low, medium and high doses of Chinese medicine composition 30min before aerosolization every day. The normal group and the model group were given normal saline under the same conditions, once a day, for 7 consecutive days. After the last nebulization, the mice were euthanized, and the bronchoalveolar lavage fluid and lung tissues were obtained.

[0040] Detection indicators:

[0041] 1) Inflammation-related factors in bronchoalveolar lavage fluid;

[0042] 2) Oxidative stress indicators in mouse lung tissue.

[0043] 4. Statistical methods

[0044] The results were statistically analyzed using t-test.

[0045] 5. Experimental Results

[0046] 5.1 Effects on the levels of inflammatory factors in bronchoalveolar lavage fluid of OVA-induced asthma mouse model

[0047] Compared with the normal control group, TGF-β1, MMP-9, and TIMP-1 in the alveolar lavage fluid of mice in the model group were significantly increased (P<0.001), indicating that the model was successfully established. Compared with the model group, the content of inflammatory factors in the salbutamol sulfate group and the high and medium dose groups of the Chinese medicine composition was significantly reduced (P<0.01, P<0.05). This shows that the Chinese medicine composition has a good therapeutic effect on the inflammatory response of mice induced by OVA. The results are shown in Table 1.

[0048] Table 1 Effects on inflammatory factors in bronchoalveolar lavage fluid of OVA-induced asthma mouse model

[0049]

[0050] Note: Compared with the normal group, ### P<0.001; compared with the model group, *P<0.05, **P<0.01.

[0051] 5.2 Effects on oxidative stress levels in OVA-induced asthma mouse model

[0052] Compared with the normal control group, the activities of T-AOC, SOD, GSH-Px and CAT in the lung tissue of the model group mice were significantly reduced (P<0.001), indicating that the model was successfully established. Compared with the model group, the activities of the above indicators in the salbutamol sulfate group and the high- and medium-dose groups of the Chinese medicine composition were significantly increased (P<0.001, P<0.01). This shows that the Chinese medicine composition has a good regulatory effect on the oxidative stress of OVA-induced asthma in mice. The results are shown in Table 2.

[0053] Table 2 Effects on oxidative stress levels in OVA-induced asthma mouse model

[0054]

[0055] Note: Compared with the normal group, ### P<0.001; compared with the model group, **P<0.01, ***P<0.001.

[0056] 6. Experimental conclusion

[0057] Chinese herbal composition 3, 1.5 g crude drug / kg, can significantly regulate the oxidative stress and alleviate the inflammatory response in bronchial asthma mice, indicating that the Chinese herbal composition has a certain therapeutic effect on airway remodeling induced by OVA in asthmatic mice.

[0058] Experimental Example 3 Therapeutic Effect of Chinese Medicine Composition on OVA-Induced Rat Asthma Model 1. Experimental Materials

[0059] 1.1 Animals

[0060] 60 SD rats, male, SPF grade, weighing 250-270 g, were purchased from Sibeifu (Beijing) Biotechnology Co., Ltd.

[0061] Breeding environment: room temperature 20-26℃, relative humidity controlled at 40-70%, and breeding density of 5 per cage.

[0062] 1.2 Drugs

[0063] The Chinese medicine composition was prepared according to the method of Example 1 and provided by Jiangsu Kangyuan Pharmaceutical Co., Ltd.; dexamethasone sodium phosphate injection (Guizhou Guangzheng Pharmaceutical Co., Ltd., batch number 19032034); chloral hydrate (Sinopharm Chemical Reagent Co., Ltd., batch number 20200320); ovalbumin OVA (Sigma, USA, batch number SLCB8249); aluminum hydroxide (Al(OH)3) (Aladdin, batch number H2106415); physiological saline (Chenxin Pharmaceutical Co., Ltd., batch number 2101282721).

[0064] 1.3 Instruments

[0065] Electronic balance (Sartorius Scientific Instruments, model BS224S); low-temperature centrifuge (eppendorf, Germany, model 5804R); purified water instrument (Millipore, Germany, model: Milli-Q Plus); animal weight scale (Shanghai Xiangchuan Electronic Scale Co., Ltd., model: CX-SC-DA); ELISA reader (Megu Molecular, USA, model Flexstation3); cough and wheeze inducing instrument (Shanghai Xinruan, model XR-YLS-8A).

[0066] 2. Dosage design

[0067] The daily dosage of the Chinese medicine composition is 14.64 g of crude drug / day. According to the body surface area conversion method, the equivalent dose for rats is 14.64 g / 60 kg*6.2=1.51 g of crude drug / kg. According to the 1 / 4:1 / 2:1 dosing method, the low dose is 0.38 g of crude drug / kg and the medium dose is 0.76 g of crude drug. Intragastric administration, 0.1 mL / 10 g, once a day.

[0068] The dosage of dexamethasone sodium phosphate injection is 14.5 mg / day. According to the body surface area conversion method, the equivalent dose for rats is 14.5 mg / 60 kg*6.2=1.5 mg / kg.

[0069] 3. Experimental Methods

[0070] SD rats were adaptively fed for 3 days and allowed to eat feed and water freely. They were randomly divided into a normal control group, a model control group, a dexamethasone control group, and a high-, medium-, and low-dose group of the Chinese medicine composition according to their body weight, with 10 rats in each group.

[0071] 10% OVA and 10% Al(OH) 3Suspension, except for the animals in the normal group, all other animals were sensitized by intraperitoneal injection of 1 mL on the first day, and the above process was repeated once on the 8th day to strengthen sensitization. The normal group and the model group were intraperitoneally injected with an equal volume of 0.9% saline at the same time. On the 15th day, the model rats were placed in a cough-inducing asthma induction instrument, and 1% OVA solution was atomized and inhaled to induce asthma. The symptoms were successfully stimulated by the rats showing shortness of breath, scratching the nose, sneezing, etc., once / d, 30min / time, for 2 consecutive weeks. At the same time, from the 15th day of the experiment, each group began to be intraperitoneally injected and gavaged, dexamethasone group (1.5mg / kg), low, medium and high doses of Chinese medicine combination (4.29g / kg, 8.58g / kg, 17.15g / kg), once / d, for 2 consecutive weeks.

[0072] One hour after the last challenge, the rats in each group were anesthetized with 10% chloral hydrate, and blood was collected from the abdominal aorta, and the bronchoalveolar lavage fluid and lung tissue of the rats were obtained.

[0073] Detection indicators:

[0074] 1) Levels of related cytokines in rat serum and bronchoalveolar lavage fluid;

[0075] 2) Histamine levels in rat lung tissue.

[0076] 4. Statistical methods

[0077] The results were statistically analyzed using t-test.

[0078] 5. Experimental Results

[0079] 5.1 Effects of cytokines on OVA-induced asthma in rats

[0080] Compared with the normal control group, the levels of TNFα, IL-4, and IL-1β in the serum and bronchoalveolar lavage fluid of the model group rats were significantly increased (P<0.001); compared with the model group, the levels of TNFα, IL-4, and IL-1β in the dexamethasone group were significantly reduced (P<0.001), and the levels of the above indicators in the medium and high dose groups of the Chinese medicine composition were also significantly reduced (P<0.01). The results are shown in Tables 3 and 4.

[0081] Table 3 Effects on serum cytokines in OVA-induced asthma rat model

[0082]

[0083] Note: Compared with the normal control group, ### P<0.001; compared with the model control group, ***P<0.001, **P<0.01.

[0084] Table 4 Effects on cytokines in bronchoalveolar lavage fluid of OVA-induced asthma rat model

[0085]

[0086] Note: Compared with the normal control group, ### P<0.001; compared with the model control group, ***P<0.001, **P<0.01.

[0087] 5.2 Effects on OVA-induced histamine levels in rat lung tissue

[0088] Compared with the normal control group, the histamine level in the lung tissue of the model group rats was significantly increased (P<0.001); after dexamethasone treatment, the histamine level in the lung tissue of the dexamethasone group animals was significantly reduced compared with the model control group (P<0.001); after treatment with the Chinese medicine composition, the histamine level in the medium and high dose groups of animals was also significantly reduced (P<0.01). The results are shown in Table 5.

[0089] Table 5 Effects on histamine levels in lung tissue of OVA-induced asthma rat model

[0090]

[0091] 6. Experimental conclusion

[0092] The Chinese medicine composition of 1.51 and 0.76 g crude drug / kg can significantly inhibit the levels of TNFα, IL-4, and IL-1β in the serum and bronchoalveolar lavage fluid of the rat asthma model, and reduce the histamine content in the lung tissue, indicating that the Chinese medicine composition has the effect of alleviating and improving the inflammatory response and bronchial contraction of asthmatic rats, and the Chinese medicine composition has a certain therapeutic effect on the OVA-induced rat asthma model.

[0093] The above embodiments of the present invention are merely examples for clearly illustrating the present invention, and are not intended to limit the embodiments of the present invention. For those skilled in the art, other different forms of changes or modifications can be made based on the above description. It is not necessary and impossible to list all the embodiments here. Any modifications, equivalent substitutions and improvements made within the spirit and principles of the present invention should be included in the protection scope of the claims of the present invention.

Claims

1. Use of a Chinese medicine composition in preparing a drug for treating or preventing asthma, characterized in that: The Chinese medicine composition comprises, by weight, 100-400 parts of honeysuckle, 75-300 parts of kudzu root, 100-400 parts of forsythia, 60-240 parts of burdock fruit, 60-240 parts of mint, 60-240 parts of isatis root, 75-300 parts of anemarrhena, 50-200 parts of cicada shell, and 30-120 parts of cicada shell.

2. The use according to claim 1, characterized in that: The traditional Chinese medicine composition comprises: 200-240 parts of honeysuckle, 150-180 parts of kudzu root, 200-240 parts of forsythia, 120-150 parts of burdock fruit, 120-150 parts of mint, 120-150 parts of isatis root, 150-180 parts of anemarrhena, 100-120 parts of cicada shell, and 60-80 parts of cicada shell.

3. The use according to claim 1, characterized in that: The traditional Chinese medicine composition comprises: 200 parts of honeysuckle, 150 parts of kudzu root, 200 parts of forsythia, 120 parts of burdock fruit, 120 parts of mint, 120 parts of isatis root, 150 parts of anemarrhena, 100 parts of cicada shell, and 60 parts of cicada shell.

4. The use according to claims 1-3, characterized in that The drug for treating or preventing asthma includes pharmaceutically acceptable adjuvants or additives.

5. The use according to claim 1, characterized in that: The medicine is selected from tablets, capsules, granules, pills, ointments, suspensions, solutions, suppositories or patches.

6. The use according to claim 1, characterized in that: The preparation method of the traditional Chinese medicine composition comprises the following steps: extracting volatile oil from two herbs, forsythia and mint, by steam distillation, encapsulating the obtained volatile oil with beta-cyclodextrin to obtain an inclusion compound, filtering the extract and setting aside; extracting the residues after oil extraction with water, filtering, combining the filtrate with the steam distillation extract and setting aside; decocting the remaining seven herbs with water, concentrating the extract, cooling, adding ethanol, standing, filtering, recovering ethanol, drying, obtaining dry powder, and adding the above-mentioned volatile oil inclusion compound.

7. The use according to claim 1, characterized in that: The preparation method of the Chinese medicine composition comprises the following steps: adding 10 times of water to two ingredients of forsythia and mint, extracting volatile oil by steam distillation, the extraction time is 3.0 hours, filtering the extract and setting aside; encapsulating the obtained volatile oil with 8 times of beta-cyclodextrin at 60°C for 3.0 hours to obtain an inclusion compound, which is set aside; adding 8 times of water to the residue after oil extraction, extracting for 2.0 hours, filtering, combining the filtrate with the steam distillation medicinal liquid and setting aside; adding water to the remaining seven ingredients and decocting them twice, each time for 2.0 hours, the first time with 11 times of water, the second time with 10 times of water, filtering the decoction, combining the filtrate and setting aside; combining the above two filtrates, concentrating under reduced pressure to a relative density of 1.07-1.09, cooling to room temperature, slowly adding ethanol to make the alcohol content reach 70%, fully stirring, standing for 18 hours, filtering, recovering ethanol from the filtrate under reduced pressure until there is no alcohol taste, diluting the medicinal liquid with water to a relative density of 1.03-1.05, spray drying to obtain dry powder, and adding the above volatile oil inclusion compound.

8. Use of a Chinese medicine composition in the preparation of a drug for treating or preventing inflammation, characterized in that: The Chinese medicine composition comprises, by weight, 100-400 parts of honeysuckle, 75-300 parts of kudzu root, 100-400 parts of forsythia, 60-240 parts of burdock fruit, 60-240 parts of mint, 60-240 parts of isatis root, 75-300 parts of anemarrhena, 50-200 parts of cicada shell, and 30-120 parts of cicada shell.

Images